News

2021 Benchmark framework to track pharma’s progress against superbugs

The rise of treatment-resistant bacterial and fungal diseases poses a direct threat both to modern medicine and our way of living. The Antimicrobial Resistance Benchmark provides the only independent measure of how pharmaceutical companies are responding. The methodology for 2021 prioritises the tracking of progress and a deeper exploration of the headwinds faced by biotechs driving novel R&D.

Read More...

Record number of countries contribute data revealing disturbing rates of antimicrobial resistance

A record number of countries are now monitoring and reporting on antibiotic resistance – marking a major step forward in the global fight against drug resistance. But the data they provide reveals that a worrying number of bacterial infections are increasingly resistant to the medicines at hand to treat them.

Read More...

WHO 2020 preclinical antibacterial pipeline data call open

Companies, institutions and individuals are invited to submit data on their products that are in the preclinical pipeline that fulfil the below inclusion criteria. Data submitted should be non-confidential and will be made available publicly on the WHO Global Health R&D Observatory.

Read More...

Identifying potential antibiotic leads is painfully slow, but these researchers identified 5 in only 6 years

ENABLE surpassed their goal of identifying 3 leads for new antibiotics. With several more compounds in the pipeline, the project has been extended.

Read More...

Investor Webinar: 2020 Antimicrobial Resistance (AMR) Benchmark

On 28 and 29 January, the Access to Medicine Foundation will host an investor webinar about the newly published 2020 AMR Benchmark. It will provide investors with an introduction about the materiality of AMR for the pharmaceutical industry and present the results from the most recent independent comparison of how 30 different pharmaceutical companies are responding to rising rates of drug-resistant infections.

Read More...

2020 Antimicrobial Resistance Benchmark launches on 21 January

The 2nd AMR Benchmark report will go live on Tuesday 21 January. It will give a reality check on how the biggest players in anti-infectives markets are responding to drug resistance and access challenges. After launch, the research will first be presented in a dedicated session at the 2020 WEF Annual Meeting in Davos.

Read More...